Nathalie Garçon: Adjuvants in pre-clinical and clinical development : the do and don’t
Location:WIMR Level 2 Conference Facility
Nathalie Garçon, PharmD, PhD, Chief Executive and Scientific Officer, BIOASTER Microbiology technology institute
Nathalie Garçon, PharmD, PhD is currently the chief executive (CEO) and scientific officer (CSO) of BIOASTER. She joined BIOASTER, the French technology research institute for infectiology and microbiology as chief scientific officer in July 2014. In this role, Dr Garcon directs the scientific aspect of the institute with the objective of accelerating the access to new technologies in infectious diseases that patient can benefit from. She was promoted to CEO in April 2015.Following the successful completion of two PhDs, one in biological pharmacy and the other in immunotoxicology and immunopharmacology, Dr Garçon moved to the UK for 1 year as a postdoctoral research fellow at the Royal Free Hospital in London, undertaking research on liposomes in vaccines.
She then moved to the USA where she spent 4 years at Baylor College of Medicine in Houston, Texas, first as a postdoctoral research fellow, then as assistant professor, working on vaccine delivery systems and immunopotentiators.
Dr Garçon joined SmithKline Beecham Biologicals now GlaxoSmithKline vaccines in 1990, where she set up and led the vaccine adjuvant and formulation group. She moved from this position, to head of technologies, head of research, vice president, head of global research and north America RD; and vice president, head of the global adjuvants and delivery systems centre for vaccines. In her last role within GSK vaccines before joining BIOASTER, Dr Garçon hold the position of vice president, head of adjuvants and technologies innovation centre, she provides leadership within GSK Biologicals in the fields of new vaccines technologies, from discovery to registration and commercialisation.
Nathalie Garçon is Vice President and Head of Global Adjuvant and technologies innovation centre at GSK vaccines Dr Garçon expertise in vaccinology extends from research to manufacturing, in particular immunology, adjuvant, formulation and innovation technologies, analytical methods, pre-clinical experimentation and toxicology/safety evaluation, regulatory and licensure and testing.
Dr Garçon is the 2014 laureate of the Stanley Plotkin award for vaccines and vaccine technologies. She has authored over 60 papers and book chapters, is the editor of several books, and holds more than 100 patents. Dr Garçon sits at the scientific committee of several journals and is a member of the immunity and infectious disease board of the British Medical Research Council.